# Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

> **NCT05900219** · PHASE2 · UNKNOWN · sponsor: **Shanghai Kechow Pharma, Inc.** · enrollment: 75 (estimated)

## Conditions studied

- Non-small-cell Lung Cancer

## Interventions

- **DRUG:** HL-085+Vemurafenib

## Key facts

- **NCT ID:** NCT05900219
- **Lead sponsor:** Shanghai Kechow Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-24
- **Primary completion:** 2025-09-24
- **Final completion:** 2025-09-24
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05900219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05900219, "Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05900219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*